• Publications
  • Influence
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis
Strongly decreased leucocyte counts and a reduced CD4/CD8 T cell ratio in the cerebrospinal fluid (CSF) of natalizumab (NZB)‐treated multiple sclerosis (MS) patients may have implications on centralExpand
  • 15
  • 3
Diclofenac Hypersensitivity: Antibody Responses to the Parent Drug and Relevant Metabolites
Background Hypersensitivity reactions against nonsteroidal antiinflammatory drugs (NSAIDs) like diclofenac (DF) can manifest as Type I-like allergic reactions including systemic anaphylaxis. However,Expand
  • 49
  • 2
  • PDF
The Evolution of Human Basophil Biology from Neglect towards Understanding of Their Immune Functions
Being discovered long ago basophils have been neglected for more than a century. During the past decade evidence emerged that basophils share features of innate and adaptive immunity. Nowadays,Expand
  • 11
  • 2
  • PDF
Tumefactive MS lesions under fingolimod
Objective: To report about a possible association between fingolimod treatment and tumefactive demyelinating lesions (TDL) as seen in a patient developing repeated TDL on continued fingolimodExpand
  • 55
  • 1
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy
Recently, the disappearance of oligoclonal bands (OCBs) from the cerebrospinal fluid (CSF) of a few natalizumab-treated patients with multiple sclerosis (MS) has been reported. This is interestingExpand
  • 58
  • 1
  • PDF
Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention.
Stroke is the third leading cause of death with an increasing prevalence. In previous years many important achievements and new therapeutic strategies have been established. This article provides anExpand
  • 48
  • 1
Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German–Austrian retrospective multicenter study in patients with a clinically isolated syndrome
The majority of patients presenting with a first clinical symptom suggestive of multiple sclerosis (MS) do not fulfill the MRI criteria for dissemination in space and time according to the 2010Expand
  • 29
  • 1
  • PDF
Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis
Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing- remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous systemExpand
  • 23
  • 1
  • PDF
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies
Natalizumab is a humanized monoclonal antibody directed against the alpha-4 integrin subunit of very late activation antigen-4 (VLA-4). Natalizumab neutralizing antibodies (NAB) have been found toExpand
  • 10
  • 1
Tumefactive MS lesions under fingolimod: A case report and literature review
  • 9
  • 1